Institute for Global Health, University College London, London, UK.
MRC Clinical Trials Unit at University College London, London, UK.
HIV Med. 2024 Jan;25(1):95-106. doi: 10.1111/hiv.13540. Epub 2023 Sep 5.
Hepatic steatosis is a major cause of chronic liver disease associated with several negative health outcomes. We compared the prevalence of and factors associated with steatosis in people living with and without HIV.
Older (>50 years) and younger (<50 years) people with HIV and older HIV-negative controls (>50 years) underwent liver transient elastography examination with controlled attenuation parameter (steatosis ≥238 dB/m, moderate/severe steatosis ≥280 dB/m, liver fibrosis ≥7.1 kPa). We compared groups using logistic regression/Chi-squared/Fisher's exact/Kruskal-Wallis tests.
In total, 317 participants (109 older people with HIV; 101 younger people with HIV; 107 HIV-negative controls) were predominantly white (86%) and male (76%), and 21% were living with obesity (body mass index ≥30 kg/m ). Most (97%) people with HIV had undetectable HIV RNA. The prevalence of fibrosis was 8.4%, 3.0%, and 6.5% in the three groups, respectively (p = 0.26). Fibrosis was predominately (>65%) mild. The prevalence of steatosis was the same in older people with HIV (66.4%) and controls (66.4%) but lower in younger people with HIV (37.4%; p < 0.001). After adjustment, younger people with HIV were less likely to have steatosis (odds ratio [OR] 0.26; 95% confidence interval [CI] 0.14-0.52) than controls, but male sex (OR 2.45; 95% CI 1.20-4.50) and high waist-to-hip ratio (OR 3.04; 95% CI 1.74-5.33) were associated with an increased odds of steatosis. We found no association between steatosis and HIV-related variables.
The prevalence of hepatic steatosis and fibrosis was similar between older participants regardless of HIV status. Age, sex, and abdominal obesity, but not HIV-related variables, were associated with steatosis. Interventions for controlling obesity should be integrated into routine HIV care.
肝脂肪变性是与多种负面健康结果相关的慢性肝病的主要原因。我们比较了患有和未患有 HIV 的人群中肝脂肪变性的患病率和相关因素。
接受过肝脏瞬时弹性成像检查的年龄较大(>50 岁)和较小(<50 岁)的 HIV 感染者以及年龄较大的 HIV 阴性对照者(>50 岁),采用受控衰减参数(脂肪变性≥238dB/m,中度/重度脂肪变性≥280dB/m,肝纤维化≥7.1kPa)。我们使用逻辑回归/卡方/Fisher 确切检验/Kruskal-Wallis 检验比较各组。
共有 317 名参与者(109 名年龄较大的 HIV 感染者;101 名年龄较小的 HIV 感染者;107 名 HIV 阴性对照者),主要为白人(86%)和男性(76%),21%的人患有肥胖症(体重指数≥30kg/m2)。大多数(97%)HIV 感染者的 HIV RNA 无法检测到。三组的纤维化患病率分别为 8.4%、3.0%和 6.5%(p=0.26)。纤维化主要为(>65%)轻度。年龄较大的 HIV 感染者(66.4%)和对照组(66.4%)的脂肪变性患病率相同,但年龄较小的 HIV 感染者(37.4%;p<0.001)较低。调整后,年龄较小的 HIV 感染者发生脂肪变性的可能性低于对照组(比值比 [OR] 0.26;95%置信区间 [CI] 0.14-0.52),但男性(OR 2.45;95% CI 1.20-4.50)和高腰臀比(OR 3.04;95% CI 1.74-5.33)与脂肪变性的几率增加相关。我们没有发现脂肪变性与 HIV 相关变量之间存在关联。
无论 HIV 状态如何,年龄较大的参与者的肝脂肪变性和纤维化患病率相似。年龄、性别和腹部肥胖,但与 HIV 无关的变量,与脂肪变性相关。控制肥胖的干预措施应纳入常规 HIV 护理。